• Explore /
  • Poster
  • / A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

Abstract Video & Slides Poster

Authors

null

Neil Howard Segal

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Neil Howard Segal , Eugenia Girda , Davendra Sohal , Nehal J. Lakhani , Anthony J. Olszanski , Lawrence Fong , Hyunsil Han , Kerry A. Casey , Siyu Li , Samit Ganguly , Frank A. Seebach , Melissa Divya Mathias , Meredith Pelster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04626635

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS239)

DOI

10.1200/JCO.2024.42.3_suppl.TPS239

Abstract #

TPS239

Poster Bd #

P7

Abstract Disclosures

Similar Posters

First Author: Neil Howard Segal

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.

Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.

First Author: Aparna Raj Parikh

First Author: Jiajian Liu

First Author: Omid Hamid